Bausch Health Cos (BHC) Expected to Post Earnings on Wednesday

Bausch Health Cos (NYSE:BHC) is projected to announce its Q3 2026 results after the market closes on Wednesday, October 28th. Analysts expect the company to post earnings of $1.25 per share and revenue of $2.72 billion for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 5:00 PM ET.

Bausch Health Cos (NYSE:BHC) last posted its earnings results on Wednesday, July 29th. The company reported $1.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.96 by $0.30. The business had revenue of $2.83 billion during the quarter, compared to analysts’ expectations of $2.59 billion. Bausch Health Cos had a negative return on equity of 561.95% and a negative net margin of 10.12%. On average, analysts expect Bausch Health Cos to post $4.35 EPS for the current fiscal year and $4.02 EPS for the next fiscal year.

Bausch Health Cos Stock Performance

Shares of BHC stock opened at $6.41 on Wednesday. The company has a market capitalization of $2.40 billion, a P/E ratio of -2.16 and a beta of 0.37. The company’s 50 day moving average price is $6.17 and its two-hundred day moving average price is $5.61. Bausch Health Cos has a 52 week low of $4.33 and a 52 week high of $8.00.

Insider Buying and Selling at Bausch Health Cos

In other news, insider Aimee Lenar sold 36,827 shares of the company’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $7.03, for a total transaction of $258,893.81. Following the completion of the transaction, the insider directly owned 334,853 shares of the company’s stock, valued at $2,354,016.59. This represents a 9.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 20.67% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have recently weighed in on BHC. Wall Street Zen upgraded shares of Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 1st. Weiss Ratings raised shares of Bausch Health Cos from a “sell (d-)” rating to a “sell (d)” rating in a research report on Friday, July 31st. Royal Bank Of Canada restated a “sector perform” rating and set a $9.00 price objective on shares of Bausch Health Cos in a report on Thursday, October 8th. Jefferies Financial Group raised shares of Bausch Health Cos to a “hold” rating in a research report on Wednesday, July 22nd. Finally, Zacks Research raised shares of Bausch Health Cos from a “hold” rating to a “strong-buy” rating in a research report on Monday, September 21st. One analyst has rated the stock with a Strong Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $8.00.

About Bausch Health Cos

Bausch Health Companies Inc (NYSE:BHC) is a multinational specialty pharmaceutical company focused on developing, manufacturing and commercializing branded, generic and over-the-counter medicines. Its portfolio serves several therapeutic areas, including gastroenterology, dermatology, neurology, ophthalmology, hospital products and other specialty-care markets.

The company markets products through businesses such as Salix Pharmaceuticals, Ortho Dermatologics, Solta Medical and its international pharmaceutical operations.